Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: implications for therapeutic response and monitoring
European Journal of Clinical Pharmacology · 2024
DOI: 10.1007/s00228-024-03675-9 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Clinical Pharmacology, 2024. Verfasst von Mervat M Omran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, 11796, Egypt. Mervat.omran@nci.cu.edu.eg. Hauptthemen laut MEDLINE: Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Antineoplastic Agents, Creatine Kinase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cairo University.
Abstract (Originalsprache)
Background
Imatinib treatment for certain cancers can lead to elevated creatine kinase (CK) levels, potentially indicating muscle injury, and ongoing research aims to understand the correlation between imatinib levels and creatine kinase to assess its impact on treatment response.
Methods
This single-center observational study involved 76 chronic myeloid leukemia (CML) patients receiving imatinib treatment, focusing on evaluating drug and metabolite levels using liquid chromatography–mass spectrometry (LC–MS-MS) instrumentation. Serum CK and creatine kinase-MB (CK-MB) levels were assessed using Colorimetric kits.
Results
CK and CK-MB levels were measured, CK showed a median value of 211.5 IU/l and CK-MB showed a median value of 4.4 IU/l. Comparing low and high CK groups, significant differences were found in peak and trough plasma concentrations of imatinib and its metabolites. Correlations between CK levels and pharmacokinetic parameters were explored, with notable associations identified. Binary logistic regression revealed predictors influencing the therapeutic response to imatinib and categorized expected CK levels into high or low, with peak levels of imatinib emerging as a significant predictor for CK level categorization.
Conclusion
The study highlights the link between imatinib’s pharmacokinetics and elevated CK levels, indicating a possible correlation between specific metabolites and improved treatment response. Individualized monitoring of CK levels and imatinib pharmacokinetics could enhance care for CML patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, 11796, Egypt. Mervat.omran@nci.cu.edu.eg.
- Department of Pharmacology, Faculty of Medicine, Zawia University, Zawia, Libya.
- Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
- Pharmacology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, 11796, Egypt.
- Clinical Pharmacy Practice Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo, Egypt.
Förderung
- Cairo University
Zitieren
APA
Omran, M. M., Ibrahim, A. B., Abdelfattah, R., Shouman, S. A., & Hamza, M. S. (2024). Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: implications for therapeutic response and monitoring. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-024-03675-9
Vancouver
Omran MM, Ibrahim AB, Abdelfattah R, Shouman SA, Hamza MS. Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: implications for therapeutic response and monitoring. European Journal of Clinical Pharmacology. 2024. doi:10.1007/s00228-024-03675-9
BibTeX
@article{Omran2024,
author = {Omran, Mervat M and Ibrahim, Amel B and Abdelfattah, Raafat and Shouman, Samia A and Hamza, Marwa S},
title = {Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: implications for therapeutic response and monitoring},
journal = {European Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1007/s00228-024-03675-9}
}
EUVIMED